These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7072453)

  • 1. Acetate: inhibitor of growth hormone hypersecretion in diabetic and non-diabetic uraemic subjects.
    Orskov H; Hansen AP; Hansen HE; Alberti KG; Noy GA; Nosadini R
    Acta Endocrinol (Copenh); 1982 Apr; 99(4):551-8. PubMed ID: 7072453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of arginine- and hypoglycemia- induced growth hormone release by acetate in dialyzed patients.
    Schmitz O; Hansen AP; Hansen HE; Orskov H
    Clin Nephrol; 1982 Feb; 17(2):70-6. PubMed ID: 7067169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetate suppresses growth hormone secretion in uremic patients: hemodialysis and acetate infusion experiments.
    Schmitz O; Hansen AP; Hansen HE; Orskov H; Alberti KG
    Artif Organs; 1982 May; 6(2):132-5. PubMed ID: 7125955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acetate on blood metabolites and glucose tolerance during haemodialysis in uraemic non-diabetic and diabetic subjects.
    Akanji AO; Sacks S
    Nephron; 1991; 57(2):137-43. PubMed ID: 2020339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone response to acute growth hormone releasing hormone administration in uraemic patients on haemodialysis.
    Donnay S; García-Martín F; Martin-Escobar E; De Arriba G; Agud JL; Requejo R
    Nephrol Dial Transplant; 1992; 7(3):246-50. PubMed ID: 1314998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of growth hormone response to insulin, arginine and haemodialysis in uraemic children.
    Ijaiya K
    Eur J Pediatr; 1979 Jun; 131(3):185-98. PubMed ID: 477677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of diurnal plasma prolactin rhythm in diabetic and non-diabetic uraemic patients.
    Schmitz O
    Acta Endocrinol (Copenh); 1984 Feb; 105(2):173-8. PubMed ID: 6538055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone levels in uraemic patients on haemodialysis.
    Cantalamessa L; Cremagnani L; Orsatti A; Vigna L; Buccianti G
    Nephrol Dial Transplant; 1992; 7(10):1068-9. PubMed ID: 1331885
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of uraemic anorexia with megestrol acetate].
    Fernández Lucas M; Teruel JL; Burguera V; Sosa H; Rivera M; Rodríguez Palomares JR; Marcén R; Quereda C
    Nefrologia; 2010; 30(6):646-52. PubMed ID: 21113214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalisation of growth hormone hypersecretion in uraemic diabetics and non-diabetics. Studies with artificial pancreas and artificial kidney.
    Hansen AP; Hansen HE; Orskov H; Nosadini R; Noy G; Alberti KG
    Proc Eur Dial Transplant Assoc; 1979; 16():194-7. PubMed ID: 548980
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin resistance in uraemic insulin-dependent diabetics. Effect of dialysis therapy as assessed by the artificial endocrine pancreas.
    Schmitz O; Alberti KG; Orskov H
    Acta Endocrinol (Copenh); 1984 Mar; 105(3):371-8. PubMed ID: 6367331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the nature and causes of hyperlipidaemia in uraemia, maintenance dialysis and renal transplantation.
    Ibels LS; Simons LA; King JO; Williams PF; Neale FC; Stewart JH
    Q J Med; 1975 Oct; 44(176):601-14. PubMed ID: 1105647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma acetate levels during hemodialysis.
    Desch G; Oules R; Mion C; Descomps B; De Paulet AC
    Clin Chim Acta; 1978 May; 85(3):231-41. PubMed ID: 657519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients.
    Giordano M; Manzella D; Paolisso G; Caliendo A; Varricchio M; Giordano C
    Nephrol Dial Transplant; 2001 Mar; 16(3):566-73. PubMed ID: 11239033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria.
    Biesenbach G; Auinger M; Clodi M; Prischl F; Kramar R;
    Nephrol Dial Transplant; 2005 Mar; 20(3):559-65. PubMed ID: 15671073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis.
    Ibels LS; Stewart JH; Mahony JF; Neale FC; Sheil AG
    Q J Med; 1977 Apr; 46(182):197-214. PubMed ID: 325593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin, growth hormone and insulin in hemodialyzed uremic diabetics.
    Avram MM
    Artif Organs; 1978 Nov; 2(4):382-5. PubMed ID: 743011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis.
    Sandle GI; Gaiger E; Tapster S; Goodship TH
    Clin Sci (Lond); 1987 Sep; 73(3):247-52. PubMed ID: 3652631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.
    Díez JJ; Iglesias P; Aguilera A; Bajo MA; Selgas R
    Nephrol Dial Transplant; 1999 Jul; 14(7):1704-9. PubMed ID: 10435880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients.
    Simic-Ogrizovic S; Backus G; Mayer A; Vienken J; Djukanovic L; Kleophas W
    Int J Artif Organs; 2001 Dec; 24(12):863-9. PubMed ID: 11831591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.